TADALAFIL | A211839 | TORRENT PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
ELI LILLY AND COMPANY et al v. TORRENT PHARMACEUTICALS LIMITED et al 1 patentANDA 211839tadalafil | D.N.J. | 2018-07-11 | Terminated 2018-10-09 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.1721
per ea
Lowest NADAC/Unit
$0.1031
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 13668056830TADALAFIL 20 MG TABLET | $0.1721 | EA | Generic | — | 2026-06-17 |
| 13668056730TADALAFIL 10 MG TABLET | $0.1673 | EA | Generic | — | 2026-06-17 |
| 13668056530TADALAFIL 2.5 MG TABLET | $0.1156 | EA | Generic | — | 2026-06-17 |
| 13668056630TADALAFIL 5 MG TABLET | $0.1031 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.